Showing 2651-2660 of 4166 results for "".
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2480985/Nanoscope Therapeutics announced that the first patient has been dosed in a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease. “This trial represents the second indication for our vision restoring
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- Parexel Enters Agreement with MyEyeDr to Refer Patients into Existing and Future Ophthalmology Clinical Trialshttps://modernod.com/news/parexel-enters-agreement-with-myeyedr-to-refer-patients-into-existing-and-future-ophthalmology-clinical-trials/2481298/Parexel, a clinical research organization (CRO), announced a formal agreement with MyEyeDr to refer its patients into existing and future ophthalmology clinical trials. Terms of the deal were not disclosed. Parexel and MyEyeDr are currently collaborating on recruitme
- First-Phase Clinical Trials of China’s First Covid-19 Vaccine to Last Nine Monthshttps://modernod.com/news/first-phase-clinical-trials-of-chinas-first-covid-19-vaccine-to-last-nine-months/2477423/Clinical trials of China’s first inoculation for Covid-19 will run until Dec. 31 this year, according to data made public by the Chinese Clinical Trial Registry, as rep
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat
- EMA Endorses Macustar's Work on Early AMD Clinical Trialshttps://modernod.com/news/ema-endorses-macustars-work-on-early-amd-clinical-trials/2482631/The European Medicines Agency (EMA) has issued its third 'Letter of Support' to the Macustar consortium, a European public-private partnership focused on advancing clinical trial methodologies for early-stage age-related macular degeneration (AMD). This endorsement follows the consortium&